<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03219957</url>
  </required_header>
  <id_info>
    <org_study_id>AT-01B-001</org_study_id>
    <nct_id>NCT03219957</nct_id>
  </id_info>
  <brief_title>Study of AT-527 in Healthy and HCV-Infected Subjects</brief_title>
  <official_title>A Phase I Study Assessing Single and Multiple Doses of AT-527 in Healthy and HCV-Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atea Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atea Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has multiple parts. It will assess the safety, tolerability and pharmacokinetics
      (PK) of AT-527 in healthy subjects and subjects infected with hepatitis C virus (HCV). In
      addition, the study will assess the antiviral activity of AT-527 in subjects infected with
      HCV.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Through Day 6 for subjects receiving a single dose</time_frame>
    <description>Number of subjects experiencing treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Through Day 35 for subjects receiving multiple doses.</time_frame>
    <description>Number of subjects experiencing treatment-emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of AT-527</measure>
    <time_frame>Day 1 for subjects receiving a single dose; Days 1 and 7 for subjects receiving multiple doses</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of AT-527</measure>
    <time_frame>Day 1 for subjects receiving a single dose; Days 1 and 7 for subjects receiving multiple doses</time_frame>
    <description>Area under the concentration-time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiviral Activity of AT-527</measure>
    <time_frame>Through Day 6 for subjects receiving a single dose; Through Day 35 for subjects receiving multiple doses.</time_frame>
    <description>Change from baseline in plasma HCV RNA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>AT-527</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-527</intervention_name>
    <description>Ascending doses of AT-527 administered orally.</description>
    <arm_group_label>AT-527</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects (healthy and HCV-infected subjects):

          -  Must agree to use two methods of birth control from Screening through 90 days after
             administration of the last dose of study drug

          -  Must have a negative pregnancy test at Screening and prior to dosing

          -  Minimum body weight of 50 kg

          -  Willing to comply with the study requirements and to provide written informed consent

        Additional inclusion criteria for HCV-infected subjects:

          -  Must have not received prior treatment for HCV infection

          -  Documented clinical history compatible with chronic HCV infection

          -  Plasma HCV RNA â‰¥ 5.0 log10 IU/mL at Screening.

        Exclusion Criteria:

        All subjects (healthy and HCV-infected subjects):

          -  Pregnant or breastfeeding

          -  Infected with hepatitis B virus or HIV

          -  Abuse of alcohol or drugs

          -  Use of other investigational drugs within 28 days of dosing

          -  Other clinically significant medical conditions or laboratory abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-Jian Zhou, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Atea Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-Jian Zhou, PhD</last_name>
    <phone>857-284-8891</phone>
    <email>zhou.xj@ateapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Moldova, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2017</study_first_submitted>
  <study_first_submitted_qc>July 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>RNA Viruses</keyword>
  <keyword>Flavivirus</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Hepatitis, Viral, Human</keyword>
  <keyword>Flaviviridae Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

